ADVASC-New regional initiative supporting transition from dengue vaccine to vaccination in Southeast Asia

Vaccine

Volumn 30, Issue 38, 2012, Pages 5587-5588

  Thisyakorn, Usa ^a,b  

^a CHULALONGKORN UNIVERSITY   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Advocacy; ASEAN; Dengue; Vaccination

Indexed keywords

DENGUE VACCINE;

ASEAN MEMBER STATES DENGUE VACCINATION ADVOCACY STEERING COMMITTEE; DENGUE; HEALTH CARE ORGANIZATION; HUMAN; INTERNATIONAL COOPERATION; LETTER; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; RISK REDUCTION; SOUTHEAST ASIA; VACCINATION;

ASIA, SOUTHEASTERN; DENGUE; DENGUE VACCINES; HEALTH SERVICES ADMINISTRATION; HUMANS; INTERNATIONAL COOPERATION; VACCINATION;

EID: 84864739243     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.05.087     Document Type: Letter

References (6)

1. Lam S.K. Dengue v2V - new global initiative supporting transition from vaccine to vaccination. Vaccine 2010, 28(February (9)):2060-2061.
2. WHO [Internet]. Dengue and severe dengue. Fact sheet No. 117. Available from: http://www.who.int/mediacentre/factsheets/fs117/en/. 2012 [cited 02 April 2012].
3. Wilder-Smith A., Gubler D.J. Geographic expansion of dengue: the impact of international travel. Med Clin North Am 2008, 92(November (6)):1377-1390. x.
4. Guzman M.G., Halstead S.B., Artsob H., Buchy P., Farrar J., Gubler D.J., et al. Dengue: a continuing global threat. Nat Rev Microbiol 2010, 8(Suppl. 12):S7-S16.
5. WHO Regional office for South-East Asia. Comprehensive guidelines for prevention and control of dengue and dengue haemorrhagic fever. 2011, Revised and expanded edition.
6. Guy B., Barrere B., Malinowski C., Saville M., Teyssou R., Lang J. From research to Phase III: Preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. Vaccine 2011, 29(July (42)):7229-7241.